200 related articles for article (PubMed ID: 18690434)
1. A stable neurotensin-based radiopharmaceutical for targeted imaging and therapy of neurotensin receptor-positive tumours.
García-Garayoa E; Bläuenstein P; Blanc A; Maes V; Tourwé D; Schubiger PA
Eur J Nucl Med Mol Imaging; 2009 Jan; 36(1):37-47. PubMed ID: 18690434
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of DOTA-chelated neurotensin analogs with spacer-enhanced biological performance for neurotensin-receptor-1-positive tumor targeting.
Jia Y; Shi W; Zhou Z; Wagh NK; Fan W; Brusnahan SK; Garrison JC
Nucl Med Biol; 2015 Nov; 42(11):816-23. PubMed ID: 26302836
[TBL] [Abstract][Full Text] [Related]
3. Stabilised 111In-labelled DTPA- and DOTA-conjugated neurotensin analogues for imaging and therapy of exocrine pancreatic cancer.
de Visser M; Janssen PJ; Srinivasan A; Reubi JC; Waser B; Erion JL; Schmidt MA; Krenning EP; de Jong M
Eur J Nucl Med Mol Imaging; 2003 Aug; 30(8):1134-9. PubMed ID: 12768332
[TBL] [Abstract][Full Text] [Related]
4. Double-stabilized neurotensin analogues as potential radiopharmaceuticals for NTR-positive tumors.
García-Garayoa E; Maes V; Bläuenstein P; Blanc A; Hohn A; Tourwé D; Schubiger PA
Nucl Med Biol; 2006 May; 33(4):495-503. PubMed ID: 16720241
[TBL] [Abstract][Full Text] [Related]
5.
Wu W; Yu F; Zhang P; Bu T; Fu J; Ai S; You Q; Shi L; Shao G; Wang F; Hodolic M; Guo H
J Nucl Med; 2022 Sep; 63(9):1394-1400. PubMed ID: 35177423
[TBL] [Abstract][Full Text] [Related]
6. Preclinical evaluation of a new, stabilized neurotensin(8--13) pseudopeptide radiolabeled with (99m)tc.
García-Garayoa E; Bläuenstein P; Bruehlmeier M; Blanc A; Iterbeke K; Conrath P; Tourwé D; Schubiger PA
J Nucl Med; 2002 Mar; 43(3):374-83. PubMed ID: 11884498
[TBL] [Abstract][Full Text] [Related]
7. Novel bioactive and stable neurotensin peptide analogues capable of delivering radiopharmaceuticals and molecular beacons to tumors.
Achilefu S; Srinivasan A; Schmidt MA; Jimenez HN; Bugaj JE; Erion JL
J Med Chem; 2003 Jul; 46(15):3403-11. PubMed ID: 12852770
[TBL] [Abstract][Full Text] [Related]
8. New neurotensin analogue radiolabeled by 99m-technetium as a potential agent for tumor identification.
Emrarian I; Sadeghzadeh N; Abedi SM; Abediankenari S
Chem Biol Drug Des; 2018 Jan; 91(1):304-313. PubMed ID: 28816013
[TBL] [Abstract][Full Text] [Related]
9. Development of [
Wang M; Zhang H; Wang H; Feng H; Deng H; Wu Z; Lu H; Li Z
Mol Pharm; 2018 Aug; 15(8):3093-3100. PubMed ID: 29889537
[TBL] [Abstract][Full Text] [Related]
10. Novel DOTA-neurotensin analogues for 111In scintigraphy and 68Ga PET imaging of neurotensin receptor-positive tumors.
Alshoukr F; Prignon A; Brans L; Jallane A; Mendes S; Talbot JN; Tourwé D; Barbet J; Gruaz-Guyon A
Bioconjug Chem; 2011 Jul; 22(7):1374-85. PubMed ID: 21662976
[TBL] [Abstract][Full Text] [Related]
11. [99mTc]Demotensin 5 and 6 in the NTS1-R-targeted imaging of tumours: synthesis and preclinical results.
Maina T; Nikolopoulou A; Stathopoulou E; Galanis AS; Cordopatis P; Nock BA
Eur J Nucl Med Mol Imaging; 2007 Nov; 34(11):1804-14. PubMed ID: 17594090
[TBL] [Abstract][Full Text] [Related]
12. Novel neurotensin analogues for radioisotope targeting to neurotensin receptor-positive tumors.
Alshoukr F; Rosant C; Maes V; Abdelhak J; Raguin O; Burg S; Sarda L; Barbet J; Tourwé D; Pelaprat D; Gruaz-Guyon A
Bioconjug Chem; 2009 Aug; 20(8):1602-10. PubMed ID: 19610615
[TBL] [Abstract][Full Text] [Related]
13. Optimizing the Profile of [
Kanellopoulos P; Nock BA; Krenning EP; Maina T
Int J Mol Sci; 2020 Oct; 21(21):. PubMed ID: 33114537
[TBL] [Abstract][Full Text] [Related]
14. In vitro and in vivo evaluation of new radiolabeled neurotensin(8-13) analogues with high affinity for NT1 receptors.
García-Garayoa E; Allemann-Tannahill L; Bläuenstein P; Willmann M; Carrel-Rémy N; Tourwé D; Iterbeke K; Conrath P; Schubiger PA
Nucl Med Biol; 2001 Jan; 28(1):75-84. PubMed ID: 11182567
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and Evaluation of 64Cu-DOTA-NT-Cy5.5 as a Dual-Modality PET/Fluorescence Probe to Image Neurotensin Receptor-Positive Tumor.
Deng H; Wang H; Wang M; Li Z; Wu Z
Mol Pharm; 2015 Aug; 12(8):3054-61. PubMed ID: 26162008
[TBL] [Abstract][Full Text] [Related]
16. Radionuclide imaging of small-cell lung cancer (SCLC) using 99mTc-labeled neurotensin peptide 8-13.
Zhang K; An R; Gao Z; Zhang Y; Aruva MR
Nucl Med Biol; 2006 May; 33(4):505-12. PubMed ID: 16720242
[TBL] [Abstract][Full Text] [Related]
17. Investigation of the Biological Impact of Charge Distribution on a NTR1-Targeted Peptide.
Jia Y; Zhang W; Fan W; Brusnahan S; Garrison J
Bioconjug Chem; 2016 Nov; 27(11):2658-2668. PubMed ID: 27661393
[TBL] [Abstract][Full Text] [Related]
18. Facile Preparation of a Thiol-Reactive (18)F-Labeling Agent and Synthesis of (18)F-DEG-VS-NT for PET Imaging of a Neurotensin Receptor-Positive Tumor.
Wu Z; Li L; Liu S; Yakushijin F; Yakushijin K; Horne D; Conti PS; Li Z; Kandeel F; Shively JE
J Nucl Med; 2014 Jul; 55(7):1178-84. PubMed ID: 24854793
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of neurotensin receptor 1 as a potential imaging target in pancreatic ductal adenocarcinoma.
Yin X; Wang M; Wang H; Deng H; He T; Tan Y; Zhu Z; Wu Z; Hu S; Li Z
Amino Acids; 2017 Aug; 49(8):1325-1335. PubMed ID: 28536844
[TBL] [Abstract][Full Text] [Related]
20. Monitoring therapeutic response of human ovarian cancer to trastuzumab by SPECT imaging with (99m)Tc-peptide-Z(HER2:342).
Zhang J; Zhao X; Wang S; Wang N; Han J; Jia L; Ren X
Nucl Med Biol; 2015 Jun; 42(6):541-6. PubMed ID: 25735223
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
